These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37492039)

  • 21. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
    Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
    Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
    Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
    Gu L; Zhao Y; Wen F; Zhang D; Cai J; Chen Z
    Anticancer Drugs; 2023 Sep; 34(8):949-953. PubMed ID: 36846984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.
    Ahn MJ; Mendoza MJL; Pavlakis N; Kato T; Soo RA; Kim DW; Liam CK; Hsia TC; Lee CK; Reungwetwattana T; Geater S; Chan OSH; Prasongsook N; Solomon BJ; Nguyen TTH; Kozuki T; Yang JC; Wu YL; Mok TSK; Tan DS; Yatabe Y
    Clin Lung Cancer; 2022 Dec; 23(8):670-685. PubMed ID: 36151006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Novel MET Exon 14 Skipping Variants in Non-Small Cell Lung Cancer Patients: A Prototype Workflow Involving in Silico Prediction and RT-PCR.
    Das R; Jakubowski MA; Spildener J; Cheng YW
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and future treatment options for
    Hong L; Zhang J; Heymach JV; Le X
    Ther Adv Med Oncol; 2021; 13():1758835921992976. PubMed ID: 33643443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
    Lee JK; Madison R; Classon A; Gjoerup O; Rosenzweig M; Frampton GM; Alexander BM; Oxnard GR; Venstrom JM; Awad MM; Schrock AB
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34476332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of
    Yu Y; Zhang Q; Zhang J; Lu S
    J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting
    Miao L; Qiu T; Li Y; Li J; Jiang X; Liu M; Zhang X; Jiang J; Zhang H; Wang Y; Li X; Ying J; Li M
    Transl Lung Cancer Res; 2024 Jun; 13(6):1232-1246. PubMed ID: 38973946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
    Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
    Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples.
    O'Brien O; Wright MC; O'Brien C; Geoghegan O; Leonard N; Nicholson S; Cuffe S; Fabre A; Jochum W; Joerger M; Gray SG; Finn SP
    Diagnostics (Basel); 2019 Jan; 9(1):. PubMed ID: 30669306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.
    Sui JSY; Finn SP; Gray SG
    Methods Mol Biol; 2021; 2279():145-155. PubMed ID: 33683691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gumarontinib in patients with non-small-cell lung cancer harbouring
    Yu Y; Zhou J; Li X; Goto K; Min X; Nishino K; Cui J; Wu L; Sakakibara J; Shu Y; Dong X; Li L; Yoneshima Y; Zhou C; Li X; Zhang Y; Huang D; Zang A; Zhang W; Wang X; Zhang L; Bai C; Fang J; Cao L; Zhao Y; Yu Y; Shi M; Zhong D; Li F; Li M; Wu Q; Zhou J; Sun M; Lu S
    EClinicalMedicine; 2023 May; 59():101952. PubMed ID: 37096188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report.
    Chen Z; Zhu F; Li C; Li J; Cheng B; Xiong S; Zhong R; Liang W; He J
    Ann Transl Med; 2021 Mar; 9(5):424. PubMed ID: 33842645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Current Landscape for
    Desai A; Cuellar S
    J Adv Pract Oncol; 2022 Jul; 13(5):539-544. PubMed ID: 35910499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report.
    Li R; Liu X; Xu Y; Zhao J; Zhong W; Gao X; Chen M; Wang M
    Thorac Cancer; 2024 Nov; 15(32):2339-2343. PubMed ID: 39343987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world insights into patients with advanced NSCLC and MET alterations.
    Bittoni M; Yang JC; Shih JY; Peled N; Smit EF; Camidge DR; Arasada RR; Oksen D; Boutmy E; Stroh C; Johne A; Carbone DP; Paik PK
    Lung Cancer; 2021 Sep; 159():96-106. PubMed ID: 34320421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival outcomes and prognostic factors of lung cancer patients with the
    Gow CH; Hsieh MS; Chen YL; Liu YN; Wu SG; Shih JY
    Front Oncol; 2023; 13():1113696. PubMed ID: 36969059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.